Publications by authors named "Fernandez-Roldan M"
Article Synopsis
- - The study aims to improve the classification and treatment of systemic autoimmune diseases by identifying molecular clusters, moving beyond traditional clinical diagnosis methods.
- - Researchers analyzed blood samples from 955 patients and 267 healthy controls, discovering four distinct clusters: three linked to inflammatory responses and one related to low disease activity associated with healthy controls.
- - The findings suggest that these molecular clusters are stable over time and can aid in understanding disease mechanisms and improving treatment strategies, potentially changing how systemic autoimmune diseases are approached in clinical settings.
Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
BMJ Open
November 2020
Introduction: About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration of sarilumab (an IL-6 receptor inhibitor) in hospitalised patients with COVID-19, pulmonary infiltrates and a high IL-6 or D-dimer serum level could reduce the progression of ARDS requiring high-flow nasal oxygen or mechanical ventilation (non-invasive or invasive).
Methods And Analysis: Phase II, open-label, randomised, multicentre, controlled clinical trial to study the efficacy and safety of the administration of two doses of sarilumab (200 and 400 mg) plus best available therapy (BAT) in hospitalised adults with COVID-19 presenting cytokine release syndrome.